NEOS Investment Management LLC increased its stake in shares of The Clorox Company (NYSE:CLX – Free Report) by 51.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,261 shares of the company’s stock after purchasing an additional 4,510 shares during the quarter. NEOS Investment Management LLC’s holdings in Clorox were worth $1,635,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of CLX. Savvy Advisors Inc. increased its stake in shares of Clorox by 1.4% during the 2nd quarter. Savvy Advisors Inc. now owns 6,395 shares of the company’s stock worth $768,000 after purchasing an additional 91 shares during the last quarter. Canandaigua National Bank & Trust Co. boosted its holdings in Clorox by 0.8% in the third quarter. Canandaigua National Bank & Trust Co. now owns 11,196 shares of the company’s stock worth $1,380,000 after purchasing an additional 94 shares in the last quarter. State of Michigan Retirement System increased its position in Clorox by 0.3% during the second quarter. State of Michigan Retirement System now owns 33,551 shares of the company’s stock worth $4,028,000 after buying an additional 100 shares during the last quarter. Blue Trust Inc. raised its holdings in Clorox by 8.5% during the third quarter. Blue Trust Inc. now owns 1,333 shares of the company’s stock valued at $164,000 after buying an additional 104 shares in the last quarter. Finally, Westhampton Capital LLC lifted its position in shares of Clorox by 0.5% in the third quarter. Westhampton Capital LLC now owns 23,150 shares of the company’s stock worth $2,854,000 after buying an additional 107 shares during the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.
Clorox Stock Performance
Shares of NYSE CLX opened at $123.51 on Friday. The firm has a market capitalization of $14.93 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 0.60 and a beta of 0.59. The Clorox Company has a one year low of $96.66 and a one year high of $159.04. The business has a fifty day simple moving average of $109.75 and a 200 day simple moving average of $113.68. The company has a current ratio of 0.74, a quick ratio of 0.48 and a debt-to-equity ratio of 71.03.
Key Headlines Impacting Clorox
Here are the key news stories impacting Clorox this week:
- Positive Sentiment: Zacks raised its FY2028 EPS view to $7.23 and upgraded select quarterly/annual estimates (including Q1 2028 to $1.37 and Q4 2026/2027 increases), signaling modestly better forward earnings visibility that can support the stock.
- Positive Sentiment: Clorox published a consumer research report “Home Care Redefined” that underscores evolving demand for wellness- and convenience-oriented home-care products — a strategic tailwind for branded consumer staples. Home Care Redefined
- Neutral Sentiment: Management presented at the Consumer Analyst Group of New York (CAGNY) conference; slides and prepared remarks provide more detail on strategy, cost actions and growth initiatives — useful for longer-term positioning but not an immediate earnings surprise. CAGNY Slides Transcript
- Negative Sentiment: Zacks trimmed multiple near-term quarterly EPS forecasts (several Q2–Q3 2026/2027 cuts and FY2027 lowered to $6.74), reflecting caution about near-term volume/mix or cost pressure — a potential headwind for sentiment and short-term guidance expectations.
- Negative Sentiment: Wells Fargo issued a “Hold” on CLX (reported as “receives a Hold”), which keeps sell-side sentiment neutral-to-cautious and may limit near-term upside from upgrades. Wells Fargo Hold
Analysts Set New Price Targets
CLX has been the topic of a number of analyst reports. Rothschild & Co Redburn set a $117.00 price objective on Clorox in a report on Friday, February 13th. Weiss Ratings cut Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, February 4th. BNP Paribas Exane raised shares of Clorox from an “underperform” rating to a “neutral” rating in a research report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Clorox from $114.00 to $112.00 and set a “hold” rating for the company in a research note on Wednesday, February 4th. Finally, UBS Group raised their target price on shares of Clorox from $115.00 to $121.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Clorox presently has an average rating of “Reduce” and a consensus target price of $118.73.
Get Our Latest Analysis on CLX
About Clorox
The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.
Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.
See Also
- Five stocks we like better than Clorox
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
